Thymocytes were cultured as above on OP9-DL1 and either 1 µM ruxolitinib (LC Laboratories) or DMSO (vehicle control; Thermo Fisher Scientific) were added and the cells were analyzed for cell surface markers by flow cytometry as indicated. For RNA analysis, the cells were sorted for GFP− and GFP+ populations and RNA was extracted using the RNAqueous-micro kit (Ambion). Lmo2 RNA levels were measured using the same qRT-PCR assay as above.
For the in vivo studies, animals were sublethally irradiated and transplanted with 5,000 cells from 2 independent ETP-ALL cell lines, S801.2 and S1520.2. 2 d after transplant, treatment was initiated with ruxolitinib (Chemitek) at a dose of 60 mg/kg twice a day by oral gavage or vehicle (5% methylcellulose; Sigma-Aldrich) twice daily for 27 d. Animals were monitored for signs of illness or hematological abnormalities and the endpoint was survival.